Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/20/2026

1. TGT
2. EL
3. SPY
4. BILL
5. MRK
6. MRNA
7. ADI
8. LOW
9. TJX
10. SPCX

Go back to Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Biogen (BIIB) PT Lowered to $260 at RBC Capital

October 31, 2024 6:31 AM EDT

RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $260.00 (from $269.00) while maintaining a Outperform rating.

The analyst comments "3Q showed BIIB remains a company in transition, with some bright spots like ex-U.S. Leqembi, improving operating... More

Biogen (BIIB) PT Raised to $315 at Piper Sandler

October 30, 2024 4:54 PM EDT

Piper Sandler analyst Christopher Raymond raised the price target on Biogen (NASDAQ: BIIB) to $315.00 (from $307.00) while maintaining a Overweight rating.

The analyst comments "Remain OW rated on BIIB shares after a solid Q324 beat/FY24 guidance raise. While some may quibble... More

Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)

October 30, 2024 4:37 PM EDT

Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $290.00 price target on Biogen (NASDAQ: BIIB).

The analyst comments "BIIB posted in-line 3Q revenue, inclusive of Leqembi's beat and Skyclarys' miss, and higher EPS per cost-savings. Leqembi's launch remains affected by infrastructure/logistical challenges, where we continue to expect a gradual, albeit progressing, uptake curve and are... More